Paul Meggs
Obstetrics & Gynecology · Frisco, TXNPI 1548360118
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $225,348 of the $253,166 with a category attached, or 89.0%. AbbVie accounts for 87.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $88,280 and has fallen 92.3% since, to $6,755 in 2025. Among obstetrics & gynecology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 469 payments — averaging $539.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$222K
- Astellas Pharma US Inc$28K
- Biohaven Pharmaceuticals, Inc.$2K
- Kvk-tech, Inc.$198
- Currax Pharmaceuticals LLC$179
- Amgen$152
- plus $614 from 19 others
What the payments were for
- Consulting fees$1,2170%
- Speaking & faculty fees$225,34889%
- Travel & lodging$18,3817%
- Food & beverage$8,0383%
- Education$1820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 368 | $221,896 |
| Astellas Pharma US Inc | 29 | $28,496 |
| Biohaven Pharmaceuticals, Inc. | 10 | $1,630 |
| Kvk-tech, Inc. | 10 | $198 |
| Currax Pharmaceuticals LLC | 13 | $179 |
| Amgen | 3 | $152 |
| Mayne Pharma Commercial LLC | 3 | $79 |
| Avion Pharmaceuticals | 5 | $70 |
| Millicent US Inc | 3 | $54 |
| Exeltis, USA Inc. | 3 | $45 |
| Pfizer | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Organon | 3 | $37 |
| Agile Therapeutics, Inc. | 2 | $36 |
| Ascend Therapeutics US, LLC | 2 | $36 |
| Merck | 2 | $34 |
| Mycovia Pharmaceuticals, Inc. | 1 | $26 |
| Novo Nordisk | 1 | $24 |
| Aspira Women's Health Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Nalpropion Pharmaceuticals LLC | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
| Therapeuticsmd, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orilissa$163,031
- ORIAHNN$76,424
- Veozah$27,705
- NURTEC ODT$1,325
- EVENITY$119
How this compares
$253,166 in reported general payments places this provider in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $399 |
| Raloxifene Hcl | 18 | $317 |
| Zolmitriptan | 11 | $302 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Frisco
- Angela StoehrFrisco$123K
- Heather BartosFrisco$47K
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Dale StovallDallas$590K
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
- Catherine HansenWebster$357K
- Lisa JukesBee Cave$270K
- Susan CrockettLive Oak$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.